vs

Side-by-side financial comparison of Digimarc CORP (DMRC) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $8.9M, roughly 1.4× Digimarc CORP). Digimarc CORP runs the higher net margin — -47.2% vs -1398.3%, a 1351.1% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 2.9%). Digimarc CORP produced more free cash flow last quarter ($895.0K vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -5.3%).

Digimarc Corporation is a provider of enterprise software and services. The company's software, which includes digital identifiers, is designed to address counterfeiting, product authenticity, recycling accuracy, and supply chain traceability. Digimarc products are created for multiple industries such as apparel, consumer packaged goods, health and beauty, and automotive.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

DMRC vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.4× larger
RNA
$12.5M
$8.9M
DMRC
Growing faster (revenue YoY)
RNA
RNA
+431.1% gap
RNA
434.0%
2.9%
DMRC
Higher net margin
DMRC
DMRC
1351.1% more per $
DMRC
-47.2%
-1398.3%
RNA
More free cash flow
DMRC
DMRC
$157.8M more FCF
DMRC
$895.0K
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-5.3%
DMRC

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DMRC
DMRC
RNA
RNA
Revenue
$8.9M
$12.5M
Net Profit
$-4.2M
$-174.4M
Gross Margin
63.5%
Operating Margin
-48.2%
-1513.5%
Net Margin
-47.2%
-1398.3%
Revenue YoY
2.9%
434.0%
Net Profit YoY
51.4%
-117.0%
EPS (diluted)
$-0.18
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DMRC
DMRC
RNA
RNA
Q4 25
$8.9M
Q3 25
$7.6M
$12.5M
Q2 25
$8.0M
$3.8M
Q1 25
$9.4M
$1.6M
Q4 24
$8.7M
$3.0M
Q3 24
$9.4M
$2.3M
Q2 24
$10.4M
$2.0M
Q1 24
$9.9M
$3.5M
Net Profit
DMRC
DMRC
RNA
RNA
Q4 25
$-4.2M
Q3 25
$-8.2M
$-174.4M
Q2 25
$-8.2M
$-157.3M
Q1 25
$-11.7M
$-115.8M
Q4 24
$-8.6M
$-102.3M
Q3 24
$-10.8M
$-80.4M
Q2 24
$-9.3M
$-70.8M
Q1 24
$-10.3M
$-68.9M
Gross Margin
DMRC
DMRC
RNA
RNA
Q4 25
63.5%
Q3 25
58.3%
Q2 25
58.8%
Q1 25
65.0%
Q4 24
60.8%
Q3 24
62.4%
Q2 24
66.1%
Q1 24
62.5%
Operating Margin
DMRC
DMRC
RNA
RNA
Q4 25
-48.2%
Q3 25
-109.7%
-1513.5%
Q2 25
-105.2%
-4448.7%
Q1 25
-128.9%
-8360.9%
Q4 24
-105.1%
-4069.6%
Q3 24
-120.4%
-4200.9%
Q2 24
-96.2%
-4040.4%
Q1 24
-109.2%
-2178.6%
Net Margin
DMRC
DMRC
RNA
RNA
Q4 25
-47.2%
Q3 25
-106.9%
-1398.3%
Q2 25
-102.6%
-4089.3%
Q1 25
-125.2%
-7360.0%
Q4 24
-99.9%
-3439.5%
Q3 24
-113.9%
-3441.7%
Q2 24
-89.3%
-3461.8%
Q1 24
-104.0%
-1943.4%
EPS (diluted)
DMRC
DMRC
RNA
RNA
Q4 25
$-0.18
Q3 25
$-0.38
$-1.27
Q2 25
$-0.38
$-1.21
Q1 25
$-0.55
$-0.90
Q4 24
$-0.40
$-0.80
Q3 24
$-0.50
$-0.65
Q2 24
$-0.43
$-0.65
Q1 24
$-0.50
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DMRC
DMRC
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$12.9M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$40.2M
$1.9B
Total Assets
$53.0M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DMRC
DMRC
RNA
RNA
Q4 25
$12.9M
Q3 25
$12.6M
$350.2M
Q2 25
$16.1M
$243.9M
Q1 25
$21.6M
$254.2M
Q4 24
$28.7M
$219.9M
Q3 24
$33.7M
$370.2M
Q2 24
$41.5M
$575.8M
Q1 24
$48.9M
$471.4M
Stockholders' Equity
DMRC
DMRC
RNA
RNA
Q4 25
$40.2M
Q3 25
$41.4M
$1.9B
Q2 25
$46.5M
$1.2B
Q1 25
$50.0M
$1.3B
Q4 24
$61.4M
$1.4B
Q3 24
$70.2M
$1.5B
Q2 24
$77.2M
$1.2B
Q1 24
$84.5M
$830.9M
Total Assets
DMRC
DMRC
RNA
RNA
Q4 25
$53.0M
Q3 25
$55.4M
$2.1B
Q2 25
$60.7M
$1.4B
Q1 25
$66.5M
$1.5B
Q4 24
$75.8M
$1.6B
Q3 24
$85.0M
$1.6B
Q2 24
$93.4M
$1.3B
Q1 24
$99.7M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DMRC
DMRC
RNA
RNA
Operating Cash FlowLast quarter
$991.0K
$-156.2M
Free Cash FlowOCF − Capex
$895.0K
$-156.9M
FCF MarginFCF / Revenue
10.0%
-1257.6%
Capex IntensityCapex / Revenue
1.1%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-12.3M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DMRC
DMRC
RNA
RNA
Q4 25
$991.0K
Q3 25
$-2.6M
$-156.2M
Q2 25
$-4.7M
$-199.7M
Q1 25
$-5.5M
$-124.8M
Q4 24
$-4.2M
$-99.9M
Q3 24
$-7.1M
$-65.6M
Q2 24
$-6.8M
$-65.0M
Q1 24
$-8.4M
$-70.4M
Free Cash Flow
DMRC
DMRC
RNA
RNA
Q4 25
$895.0K
Q3 25
$-2.8M
$-156.9M
Q2 25
$-4.9M
$-203.0M
Q1 25
$-5.5M
$-128.6M
Q4 24
$-4.2M
$-103.8M
Q3 24
$-7.2M
$-67.3M
Q2 24
$-6.9M
$-65.5M
Q1 24
$-8.5M
$-71.3M
FCF Margin
DMRC
DMRC
RNA
RNA
Q4 25
10.0%
Q3 25
-36.9%
-1257.6%
Q2 25
-61.0%
-5277.1%
Q1 25
-59.1%
-8174.3%
Q4 24
-49.1%
-3491.0%
Q3 24
-75.7%
-2881.8%
Q2 24
-66.1%
-3204.6%
Q1 24
-85.8%
-2012.3%
Capex Intensity
DMRC
DMRC
RNA
RNA
Q4 25
1.1%
Q3 25
2.9%
5.7%
Q2 25
2.5%
86.9%
Q1 25
0.6%
238.6%
Q4 24
0.2%
131.7%
Q3 24
0.7%
72.9%
Q2 24
0.3%
26.0%
Q1 24
1.1%
25.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DMRC
DMRC

Subscription$5.3M60%
The Government$3.6M41%

RNA
RNA

Segment breakdown not available.

Related Comparisons